ArticleImmunity, inflammation and disease2026
Paeoniflorin Ameliorates Spinal Cord Injury by Controlling Apoptosis and Ferroptosis in H
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paeoniflorin Ameliorates Spinal Cord Injury by Controlling Apoptosis and Ferroptosis in HImmunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSpinal cord injury (SCI) leads to severe neurological dysfunction. Current therapeutic strategies remain limited, with poor recovery rates. Oxidative stress and ferroptosis are key mechanisms underlying secondary SCI. Paeoniflorin has anti-inflammatory, antioxidant, and neuroprotective properties; however, its role in regulating apoptosis and ferroptosis after SCI remains unclear.
methodsAn in vitro SCI model was established by treating PC12 cells with 300 μM H₂O₂ for 24 h, followed by intervention with various concentrations of paeoniflorin. Cell viability was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay, apoptosis was analyzed by flow cytometry, lipid reactive oxygen species (ROS) levels were detected by immunofluorescence, and cysteine (Cys), glutathione (GSH), and glutathione peroxidase 4 (GPX4) levels were measured using enzyme-linked immunosorbent assay (ELISA) kits. Western blotting and reverse transcription quantitative polymerase chain reaction (RT-qPCR) were performed to evaluate the expression of sirtuin 3 (SIRT3), B-cell lymphoma-2 (Bcl-2), and BCL2-Associated X (Bax). In addition, the SIRT3-specific inhibitor, 3-TYP, was used to validate the role of SIRT3 in paeoniflorin-mediated protection.
resultsPaeoniflorin increased cell viability; reduced apoptosis; suppressed ROS accumulation; and restored Cys, GSH, and GPX4 levels in a dose-dependent manner. Paeoniflorin significantly upregulated SIRT3 mRNA and protein expression. Co-treatment with 3-TYP attenuated the protective effects of paeoniflorin, indicating that the role of paeoniflorin is mediated through activation of the SIRT3 pathway.
conclusionPaeoniflorin exerts significant neuroprotective effects against SCI-induced injury by activating the SIRT3 signaling pathway and regulating apoptosis, oxidative stress, and ferroptosis, offering a novel potential therapeutic target for SCI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.